A Phase I/II Trial to Evaluate the Safety and Efficacy of iPSC-Derived Dopaminergic Progenitors in the Treatment of Parkinson's Disease
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2018
Price : $35 *
At a glance
- Drugs Dopaminergic neural progenitor cell therapy Sumitomo Dainippon Pharma (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 10 Aug 2018 New trial record
- 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, Kyoto University Hospital, in partnership with the Center for iPS Cell Research and Application (CiRA), Kyoto University, has planned physician-initiated clinical trials (this and phase III trial) for Parkinson's disease that transplants dopaminergic progenitors generated from induced pluripotent stem (iPS) cells.
- 30 Jul 2018 According to a Kyoto University media release and announcement posted on CiRAs website, the clinical trial notification was submitted to the Pharmaceutical and Medical Devices Agency on 4 Jun 2018 and the clinical trials (this and phase III trial) are scheduled to begin on 1 Aug 2018.